May 30, 2017 News by Patricia Inacio, PhD #CMSC17 – Celgene’s Investigational Therapy Ozanimod Safe, Effective in Treating Relapsing MS, Clinical Trial Finds Long-term treatment for up to 12o weeks, with theĀ investigational drug Ozanimod (RPC-1063), found to be effective and safe in patients with relapsing multiple sclerosis (MS) who participated in the RADIANCE clinical trial. Celgene, Ozanimod’s developer, presented the study, āEfficacy and Safety of Ozanimod in the Blinded Extension (120…
May 23, 2017 News by Alice MelĆ£o, MSc Results of Phase 3 Trial for Celgene’s Ozanimod Suggest Therapeutic Benefit in RMS Patients Relapsing multiple sclerosis (RMS) patients taking the investigational drug ozanimod, also known as RPC-1063, had lowerĀ relapse rate than those on weekly Avonex (interferon Ī²-1a) therapy, according toĀ CelgeneĀ in an announcement updating results of its Phase 3 RADIANCE trial. Ozanimod is a new orally administrated drug that selectively inhibits the…
February 20, 2017 News by Patricia Silva, PhD Ozanimod Reduces Multiple Sclerosis Relapse Rate, Phase 3 Trial Shows A Phase 3 clinical trial evaluating the safety and effectiveness of ozanimod (RPC-1063) in patients withĀ relapsing multiple sclerosis (RMS)Ā shows treatment reduced the disease’s annualized relapse rate (ARR), researchers reported. The Phase 3 SUNBEAM trial (NCT02294058)Ā testedĀ ozanimod, anĀ oral, selective sphingosine 1-phosphate 1 (S1PR1) and 5 (S1PR5) receptor modulator designed to…
December 23, 2016 Columns by Ed Tobias Still Waiting on Ocrevus Several months ago I wrote a blog on my personal websiteĀ aboutĀ Ocrevus (ocrelizumab), the first drug that’s designed specifically to treat primary progressive, as well as remitting, multiple sclerosis. The clinical trials forĀ Ocrevus posted excellent results. The buzz in the medical community was good, Ā and it was…
September 22, 2016 News by Joana Fernandes, PhD #ECTRIMS2016 – Treatment for Relapsing MS, Ozanimod, Shows Efficacy in 2-Year Extension of Phase 2 Study Results from the extension period of aĀ Phase 2 trial,Ā assessingĀ ozanimod as a potential treatment for relapsing-remitting multiple sclerosis, showed that the drug can effectively and safely improve clinical measures of RRMS after two years of treatment. The announcement was made by Celgene International SĆ rl, a subsidiary of Celgene Corporation,…
February 24, 2016 News by Patricia Silva, PhD Relapsing MS Treatment Showing Efficacy in Phase 2 Extension Study, Celgene Reports at ACTRIMS 2016 Celgene CorporationĀ announced theĀ results from anĀ extension studyĀ of theĀ RADIANCE Phase 2 clinical trial evaluating ozanimod in patients with relapsing multiple sclerosis (MS). The results were also presented at the recentĀ Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2016Ā in New Orleans, Louisiana. Ozanimod is a small…
January 25, 2016 News by Margarida Azevedo, MSc Mode of Action for MS Drug Showing Promise in Phase 3 Clinical Trials Uncovered In a new study, researchers at theĀ Scripps Research Institute (TSRI)Ā uncovered the molecular mechanisms behind the perceived clinicalĀ efficacyĀ of a specific drug type, sphingosine 1-phosphate receptor 1 (S1PR1) agonists, toĀ diminish the harmful immune response that leads to autoimmunity in multiple sclerosis (MS) and other diseases, while still preserving the immune system’s…
July 17, 2015 News by Charles Moore Celgene to Acquire Receptos, Advancing Leadership in Immune-Inflammatory Diseases Such As MS and IBD Summit, New Jersey based Celgene Corporation and Receptos, Inc. of San Diego, California, a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, have announced their joint signing of a definitive agreement in which Celgene will acquire Receptos. Under terms of the merger agreement,…
